Literature DB >> 12359274

Analysis of the pressor response to the K+ channel inhibitor 4-aminopyridine.

Torill Berg1.   

Abstract

The cardiovascular response to the K(+) channel inhibitor 4-aminopyridine in anaesthetized rats was analysed. 4-Aminopyridine produced a biphasic pressor response. First, it increased blood pressure, total peripheral vascular resistance, cardiac output and stroke volume. Nitric oxide synthase (NOS) inhibitor augmented the tension response; reserpine, phentolamine, propranolol, scopolamine, atropine, adrenalectomy, indomethacin, angiotensin AT(1) and endothelin ET(A) receptor antagonists had no effect. Subsequently, heart rate increased, but total peripheral vascular resistance was no longer elevated. Reserpine and propranolol abolished the tachycardia. An elevated late tension occurred after propranolol and NOS inhibitor but not reserpine or phentolamine+NOS inhibitor. The peripherally acting 3,4-diaminopyridine produced similar responses. 4-Aminopyridine contracted isolated aortic rings also after denudation. These results are compatible with that the immediate tension response resulted from closure of vascular smooth muscle K(+) channels, and that closure of presynaptic K(+) channels in peripheral sympathetic nerves subsequently activated noradrenaline release, beta-adrenoceptors and tachycardia, while nitric oxide counter-acted a concomitant alpha-adrenergic vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359274     DOI: 10.1016/s0014-2999(02)02306-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Effects of statins on vascular function of endothelin-1.

Authors:  Fatima Mraiche; Jonathan Cena; Debarsi Das; Bozena Vollrath
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

2.  Contribution of voltage-dependent K⁺ channels to metabolic control of coronary blood flow.

Authors:  Zachary C Berwick; Gregory M Dick; Steven P Moberly; Meredith C Kohr; Michael Sturek; Johnathan D Tune
Journal:  J Mol Cell Cardiol       Date:  2011-07-12       Impact factor: 5.000

3.  Plasma Norepinephrine in Hypertensive Rats Reflects α(2)-Adrenoceptor Release Control Only When Re-Uptake is Inhibited.

Authors:  Torill Berg; Sven Ivar Walaas; Bjørg Åse Roberg; Trang Thi Huynh; Jørgen Jensen
Journal:  Front Neurol       Date:  2012-11-08       Impact factor: 4.003

4.  Simultaneous parasympathetic and sympathetic activation reveals altered autonomic control of heart rate, vascular tension, and epinephrine release in anesthetized hypertensive rats.

Authors:  Torill Berg; Jørgen Jensen
Journal:  Front Neurol       Date:  2011-11-23       Impact factor: 4.003

5.  Voltage-Sensitive K(+) Channels Inhibit Parasympathetic Ganglion Transmission and Vagal Control of Heart Rate in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2015-12-08       Impact factor: 4.003

6.  β- and α2-Adrenoceptor Control of Vascular Tension and Catecholamine Release in Female Normotensive and Spontaneously Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2017-04-03       Impact factor: 4.003

7.  Angiotensin AT1 - α2C-Adrenoceptor Interaction Disturbs α2A-auto-Inhibition of Catecholamine Release in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

8.  Tyramine Reveals Failing α2-Adrenoceptor Control of Catecholamine Release and Total Peripheral Vascular Resistance in Hypertensive Rats.

Authors:  Torill Berg; Jørgen Jensen
Journal:  Front Neurol       Date:  2013-02-28       Impact factor: 4.003

9.  α2-Adrenoreceptor Constraint of Catecholamine Release and Blood Pressure Is Enhanced in Female Spontaneously Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Neurosci       Date:  2016-03-30       Impact factor: 4.677

10.  M-currents (Kv7.2-7.3/KCNQ2-KCNQ3) Are Responsible for Dysfunctional Autonomic Control in Hypertensive Rats.

Authors:  Torill Berg
Journal:  Front Physiol       Date:  2016-11-29       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.